Background: Chronic Pseudomonas aeruginosa lung infection is associated with significant morbidity and mortality in cystic fibrosis (CF). It is not known whether recent advances in care have affected the rates of chronic infection. We aimed to determine if the rates of developing new chronic P. aeruginosa infection among adolescents and adults with CF significantly changed over time. Methods: The cohort consisted of individuals with CF followed in the Cystic Fibrosis Foundation Patient Registry aged ≥13 years without chronic P. aeruginosa at baseline. Multivariable regression models accounting for within-patient correlation were used to assess the change in rate of developing chronic P. aeruginosa infection between 2003 and 2012. Results: A total of 15504 individuals were followed for a median of 5 (interquartile range, 2-9) years. The annual rates of developing new chronic P. aeruginosa decreased from 14.3% in 2003 to 6.4% in 2012. After adjusting for potential confounders, relative risk (RR) of developing chronic P. aeruginosa infection decreased significantly over time compared to 2003 (P value test of trend < .001). Compared with 2003, the RR of developing chronic P. aeruginosa infection in 2012 was 0.33 (95% confidence interval, 0.30-0.37). No significant increases in risk of chronic infections with other major CF bacterial pathogens relative to 2003 were identified. Conclusions: Among individuals with CF, a significant decrease in the risk and rates of developing chronic P. aeruginosa infection between 2003 and 2012 was observed. Whether this decline results in changes in clinical outcomes warrants further exploration.
Background: Chronic Pseudomonas aeruginosa lung infection is associated with significant morbidity and mortality in cystic fibrosis (CF). It is not known whether recent advances in care have affected the rates of chronic infection. We aimed to determine if the rates of developing new chronic P. aeruginosa infection among adolescents and adults with CF significantly changed over time. Methods: The cohort consisted of individuals with CF followed in the Cystic Fibrosis Foundation Patient Registry aged ≥13 years without chronic P. aeruginosa at baseline. Multivariable regression models accounting for within-patient correlation were used to assess the change in rate of developing chronic P. aeruginosa infection between 2003 and 2012. Results: A total of 15504 individuals were followed for a median of 5 (interquartile range, 2-9) years. The annual rates of developing new chronic P. aeruginosa decreased from 14.3% in 2003 to 6.4% in 2012. After adjusting for potential confounders, relative risk (RR) of developing chronic P. aeruginosa infection decreased significantly over time compared to 2003 (P value test of trend < .001). Compared with 2003, the RR of developing chronic P. aeruginosa infection in 2012 was 0.33 (95% confidence interval, 0.30-0.37). No significant increases in risk of chronic infections with other major CF bacterial pathogens relative to 2003 were identified. Conclusions: Among individuals with CF, a significant decrease in the risk and rates of developing chronic P. aeruginosa infection between 2003 and 2012 was observed. Whether this decline results in changes in clinical outcomes warrants further exploration.
Authors: Ronald L Gibson; Julia Emerson; Nicole Mayer-Hamblett; Jane L Burns; Sharon McNamara; Frank J Accurso; Michael W Konstan; Barbara A Chatfield; George Retsch-Bogart; David A Waltz; James Acton; Pamela Zeitlin; Peter Hiatt; Richard Moss; Judy Williams; Bonnie W Ramsey Journal: Pediatr Pulmonol Date: 2007-07
Authors: Michael W Konstan; Wayne J Morgan; Steven M Butler; David J Pasta; Marcia L Craib; Stefanie J Silva; Dennis C Stokes; Mary Ellen B Wohl; Jeffrey S Wagener; Warren E Regelmann; Charles A Johnson Journal: J Pediatr Date: 2007-06-22 Impact factor: 4.406
Authors: Nicole Mayer-Hamblett; Margaret Kloster; Margaret Rosenfeld; Ronald L Gibson; George Z Retsch-Bogart; Julia Emerson; Valeria Thompson; Bonnie W Ramsey Journal: Clin Infect Dis Date: 2015-05-13 Impact factor: 9.079
Authors: Todd MacKenzie; Alex H Gifford; Kathryn A Sabadosa; Hebe B Quinton; Emily A Knapp; Christopher H Goss; Bruce C Marshall Journal: Ann Intern Med Date: 2014-08-19 Impact factor: 25.391
Authors: Miriam M Treggiari; George Retsch-Bogart; Nicole Mayer-Hamblett; Umer Khan; Michal Kulich; Richard Kronmal; Judy Williams; Peter Hiatt; Ronald L Gibson; Terry Spencer; David Orenstein; Barbara A Chatfield; Deborah K Froh; Jane L Burns; Margaret Rosenfeld; Bonnie W Ramsey Journal: Arch Pediatr Adolesc Med Date: 2011-09
Authors: Kay A Ramsay; Harpreet Sandhu; James B Geake; Emma Ballard; Peter O'Rourke; Claire E Wainwright; David W Reid; Timothy J Kidd; Scott C Bell Journal: J Cyst Fibros Date: 2016-08-08 Impact factor: 5.482
Authors: Nitasha D Menon; Samuel Penziner; Elizabeth T Montaño; Raymond Zurich; David T Pride; Bipin G Nair; Geetha B Kumar; Victor Nizet Journal: Antimicrob Agents Chemother Date: 2022-07-06 Impact factor: 5.938
Authors: Nicole Acosta; Barbara Waddell; Alya Heirali; Ranjani Somayaji; Michael G Surette; Matthew L Workentine; Harvey R Rabin; Michael D Parkins Journal: Front Cell Infect Microbiol Date: 2020-04-24 Impact factor: 5.293
Authors: Dave P Nichols; Anthony G Durmowicz; Ann Field; Patrick A Flume; Donald R VanDevanter; Nicole Mayer-Hamblett Journal: Ann Am Thorac Soc Date: 2019-05
Authors: Diana Bilton; Tacjana Pressler; Isabelle Fajac; John Paul Clancy; Dorota Sands; Predrag Minic; Marco Cipolli; Ivanka Galeva; Amparo Solé; Alexandra L Quittner; Keith Liu; John P McGinnis; Gina Eagle; Renu Gupta; Michael W Konstan Journal: J Cyst Fibros Date: 2019-08-23 Impact factor: 5.527
Authors: Dave P Nichols; Katherine Odem-Davis; Jonathan D Cogen; Christopher H Goss; Clement L Ren; Michelle Skalland; Ranjani Somayaji; Sonya L Heltshe Journal: Am J Respir Crit Care Med Date: 2020-02-15 Impact factor: 21.405